Currently Viewing:
Evidence-Based Oncology June 2015
Cardio-Oncology: The Intersection Between Cancer and Cardiovascular Disease
Sanjeev A. Francis, MD; and Marielle Scherrer-Crosbie MD, PhD
Extending Cancer Care Past Remission: The Importance of Cardiac Toxicity Monitoring and Awareness
Constantine A. Mantz, MD
Radiation Therapy and Cardiotoxicity: A Cancer Survivor's Story
Debra Madden
Importance of a Heart Failure Disease Management Program for Chemotherapy-Induced Toxicity
Anecita Fadol, PhD, RN, FNP, FAANP
Influence of Cardiotoxic Risk on Treatment Choice in Adult Cancers
Debra Patt, MD, MPH, MBA
Cardiovascular Side Effects of Cancer Treatment Demand Attention
Surabhi Dangi-Garimella, PhD
Advancing Patient Care in Cardio-Oncology: The ACC.15 Cardio-Oncology Intensive
Tochi M. Okwuosa, DO; and Ana Barac, MD, PhD
In Conversation With a Cardiologist: Anju Nohria, MD
Surabhi Dangi-Garimella, PhD
Value of Patient-Reported Outcomes in Oncology Care
Surabhi Dangi-Garimella, PhD
Experts Discuss Medicare's New Oncology Care Model
Surabhi Dangi-Garimella, PhD
Augmenting the Immune System to Achieve Great Outcomes in Cancer Care
Laura Joszt
Defining Value in Cancer Care Treatment
Laura Joszt
Currently Reading
20 Years of Creating and Embracing Guidelines in Cancer Care
Laura Joszt
Zarxio Yet to See Light of Day in US Market
Surabhi Dangi-Garimella, PhD
Nivolumab Assigned Priority Review for First-Line in Melanoma
Surabhi Dangi-Garimella, PhD
IMS Health Report Estimates $100-Billion Global Cancer Spend in 2014
Surabhi Dangi-Garimella, PhD
Cardio-Oncology: A Sign of How Far We Have Come
Joseph Alvarnas, MD
Drop-off in Prostate Screening Stirs Controversy
Mary K. Caffrey
Preventing Anthracycline-Related Late Cardiac Effects in Childhood Cancer Survivors
Vivian I. Franco, MPH; and Steven E. Lipshultz, MD

20 Years of Creating and Embracing Guidelines in Cancer Care

Laura Joszt
On the first day of the NCCN 20th Annual Conference in Hollywood, Florida, March 12-14, 2015, panelists took a look back at the last 20 years of the NCCN and why it succeeded when others had failed before.
When the first National Comprehensive Cancer Network (NCCN) Guidelines were developed 20 years ago, even the participating members were skeptical about whether they would be able to come to an agreement and build something lasting, according to some of the people who were there at the beginning.

On the first day of the NCCN 20th Annual Conference in Hollywood, Florida, March 12-14, 2015, panelists took a look back at the last 20 years of the NCCN and why it succeeded when others had failed before. Clifford Goodman, PhD, of The Lewin Group, moderated the discussion.

The NCCN was created from 13 academic medical centers that were deeply concerned with then–first lady Hillary Clinton’s proposed healthcare plan. Representatives from these centers wanted to make some decisions that would ensure their relevance of their centers when things changed, according to Robert C. Young, MD, president of RCY Medicine. They chose to implement guidelines that would allow their centers and others to measure the quality of cancer care they were delivering against a set of agreed-upon guidelines. “Unfortunately, fear is a wonderful motivator and that turned out to be the reason why these 13 institutions that compete with each other in some sense got together,” Young said.

Both Al B. Benson III, MD, from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and Samuel Silver, MD, PhD, assistant dean for research at the University of Michigan Medical School, remembered that people weren’t sure if the cancer centers could work together. But they found everyone willing to collaborate, and they credited this cooperation to the late Roger J. Winn, MD. “What quickly became apparent with the formation of the panels and, certainly, the wisdom and efforts of Doctor Winn it became very clear that panel participation was an enjoyable activity,” Benson said. “You were working with your peers, and the discussions were serious and often on target.”

Robert Carlson, MD, the current chief executive officer of NCCN, who had been a panel chair at the time of NCCN’s inception, agreed that one of the reasons the NCCN succeeded is that it started from a place of collaboration. Coming from a new cancer center that was designated in 2005, Timothy J. Eberlein, MD, of the Siteman Cancer Center at Barnes-Jewish Hospital, explained that as a new arrival it was important to embrace the guidelines, practice the guidelines, and participate in the construction of the guidelines in order to formulate multidisciplinary care.

Lee N. Newcomer, MD, MHA, from UnitedHealthcare, admitted that 20 years ago NCCN and guidelines didn’t mean much because payers had seen others come and go, leaving behind 130-page guidelines that were essentially useless. The industry changed its tune, though. “Ten years along, you had a mature product that really did help people if you used it,” he said.

According to Dave McFadden, MS, RPh, of Gilead Sciences, Inc, industry quickly realized what these guidelines would mean, namely that if a drug wasn’t in the guideline it probably wasn’t going to get reimbursed. “The guidelines told us where we needed to generate evidence,” he explained. Guidelines have been useful for payers so that when they decide not to pay for a drug they had proof to back them up. It helped that NCCN Guidelines were available for anyone to access and look through and patients and providers could understand that payers’ decisions weren’t just about saving money, but about the best patient care.

Mary Lou Smith, JD, MBA, cofounder of the Research Advocacy Network, had patients’ best interests in mind when she became involved with the NCCN committees as the first patient representative. “The end user of the guidelines is the patient, and, therefore, that patient should be represented,” she said.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!